This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific
immunophenotype of clonal B cells in the peripheral blood. Prognostic models such as the …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

The first-in-class, once-daily Bruton tyrosine kinase (BTK) inhibitor ibrutinib is one of the
preferred standards of care for patients with relapsed or refractory (R/R) mantle cell …

Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and
relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following …

High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic
resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the …

Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic
leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes …

This Guideline was compiled according to the BSH process at https://bs-41 h. org.
uk/media/16732/bsh-guidance-development-process-dec-5-18. pdf and 42 represents best …

Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell
lymphoma (MCL), although studies have included a broad range of 1L, second-line (2L) …